Combining existing drug therapy is essential in developing new therapeutic agents in disease prevention and treatment. In preclinical investigations, combined effect of certain known drugs has been well established in treating extensive human diseases. A
Has been used intrathecally in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone with or without rituximab for first-line therapy of intermediate-grade non-Hodgkin’s lymphomas.Although radiation or topical therapy is generally used for treatment of localized histiocytic lymphoma, ...
the complement inhibitor can be formulated with a lipid-lowering agent such as an inhibitor of hydroxymethylglutaryl CoA reductase. In some embodiments, the complement inhibitor can be formulated with, or for use with, an anti-CD20 agent such as rituximab (RITUXAN®; Biogen Idec, Cambridge, ...
(e.g., adalimumab, certolizumab, etanercept, golimumab, infliximab), interleukin-1 (IL-1) receptor antagonists (e.g., anakinra), anti-CD20 monoclonal antibodies (e.g., rituximab), and selective costimulation modulators (e.g., abatacept); concomitant use has not been studied and there is a...
EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is app...
The control patients (i.e., CHOP group) received CHOP-based chemotherapy as first-line treatment from January 1, 1997 to the date of rituximab approval for each age group, and had no evidence of receiving rituximab. All patients were required to have an Ontario Cancer Registry (OCR) record...
Our Indian pharma players have had successes in the emerging markets (for example, Dr Reddy’s with the world’s first Rituximab biosimilar, Zydus Cadila’s Exemptia etc. and other players like Intas, Lupic, Cadila making headways in the emerging markets. However, Biocon is the only player ...
Rituximab was associated with increased COVID-19-related death (HR 1·68, 95% CI 1·11-2·56), with some attenuation after excluding people with haematological malignancies or organ transplants (1·54, 0·95-2·49). INTERPRETATION COVID-19 deaths and hospital admissions were...
Immunosuppressive regimens, including calcineurin inhibitors (CNI), methotrexate (MTX), mycophenolate mofetil (MMF), anti-thymocyte globulin (ATG), rituximab or T-cell depletion [8,9], represent the most common preventive methods, although treatments can vary across institutions. With regard to treatme...
ALIQOPA is a prescription medicine used to treat adults with follicular lymphoma (FL) when the disease has come back after treatment with at least two prior medicines. It is not known if ALIQOPA is safe and effective in children.